Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE).
COVID
SARS-CoV-2
gastroenteropancreatic cancer
neuroendocrine tumor
vaccines
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
25 Jan 2023
25 Jan 2023
Historique:
received:
03
01
2023
revised:
20
01
2023
accepted:
23
01
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
The coronavirus disease-19 (COVID-19) pandemic dramatically impacted oncological patients' care. Since the introduction of vaccines and the demonstration of their benefit on frail patients, COVID-19 vaccinations were indicated to also be beneficial to oncological population. However, data about the impact of anticancer-treatments and the timing between vaccinations and systemic therapy delivery were not available. We aimed to evaluate potential factors influencing the outcome of the COVID-19 vaccination in cancer patients. We prospectively collected data of patients undergoing the COVID-19 vaccination with gastro-entero-pancreatic and neuroendocrine neoplasms, treated at our institute, between 03/2021 and 12/2021. We enrolled 46 patients, 63.1% males; at the time of data collection, 86.9% had received two-doses of Pfizer-BioNTech and the rest had received the Moderna vaccine. All patients obtained a subsequent immune-response. Chemotherapy seems to determinate a significantly lower antibody response after vaccination compared to the other anti-cancer agents (
Identifiants
pubmed: 36830873
pii: biomedicines11020336
doi: 10.3390/biomedicines11020336
pmc: PMC9953014
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : private donations
ID : 1525
Références
Int Immunopharmacol. 2022 Jul;108:108774
pubmed: 35461110
PLoS One. 2021 Mar 22;16(3):e0248995
pubmed: 33750990
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720980612
pubmed: 33300414
Infez Med. 2021 Mar 1;29(1):20-36
pubmed: 33664170
Clin Chem Lab Med. 2021 Mar 15;59(8):1463-1467
pubmed: 33711225
Surg Endosc. 2022 Dec;36(12):9364-9373
pubmed: 35428894
Lancet Haematol. 2021 Oct;8(10):e681-e683
pubmed: 34487683
Front Neurol. 2022 Jan 04;12:726561
pubmed: 35058869
Ann Clin Microbiol Antimicrob. 2021 May 18;20(1):35
pubmed: 34006330
Front Physiol. 2021 Jan 12;11:571416
pubmed: 33510644
Cancer. 2017 Mar 1;123(5):841-848
pubmed: 27997703
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669
pubmed: 33629336
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924
pubmed: 33332292
Ann Oncol. 2021 Jun;32(6):787-800
pubmed: 33746047
Ann Oncol. 2020 Oct;31(10):1320-1335
pubmed: 32745693
Cancer Biother Radiopharm. 2009 Dec;24(6):659-65
pubmed: 20025545
Br J Surg. 2020 Jun;107(7):785-787
pubmed: 32191340
Nat Cancer. 2021 Dec;2(12):1305-1320
pubmed: 35121899
Front Oncol. 2020 Apr 23;10:586
pubmed: 32391270
Future Oncol. 2015;11(8):1275-90
pubmed: 25832882
Nat Med. 2021 Apr;27(4):568-569
pubmed: 33589821
Lancet Rheumatol. 2021 Nov;3(11):e789-e797
pubmed: 34514436
Clin Transl Radiat Oncol. 2022 Feb 24;34:1-6
pubmed: 35243028
Nat Rev Clin Oncol. 2021 May;18(5):313-319
pubmed: 33723371
Acta Oncol. 2020 Jun;59(6):644-651
pubmed: 32036716
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
Ann Nucl Med. 2021 Dec;35(12):1332-1341
pubmed: 34533700
J Intern Med. 2021 Apr;289(4):450-462
pubmed: 33020988
Cancer Cell. 2021 Nov 8;39(11):1442-1444
pubmed: 34706273
Lancet Infect Dis. 2019 Jun;19(6):e200-e212
pubmed: 30744963